(TGA) will permit the prescribing of MDMA 1st July, page-23

Yeah we need clarification on this for sure, so the green light is for 3,4-Methylenedioxymethamphetamine specifically and adding or removing molecules or just changing the shape of the compound would be, as Dr Winlo and Dr Piggott use the term "MDMA like", someone should ask Michael how this impacts our analogues.

We know the company is looking at a variation of the compound that has a shorter half life so that therapy sessions were able to be performed in a day and there was no need for overnight care.

I think at least we can say is the TGA is taking baby steps and while the company is already doing the work for metabolic studies with some priority compounds already sent to the USA for evaluation, at least they will have the data ready to show the TGA down the line.

I know this is off topic but there is definitely opportunity for an ongoing market for MDMA like compounds as Dr Piggott was studding the use for Parkinson's disease/Dyskinesia and the effect it when it was taken in conjunction with L-DOPA.
Dr Piggott was studying this a long time ago as his father suffers from it.

"The analogues are akin to MDMA but designed to engage different neurological targets, opening up options for potential clinical use in mental health disorders, specifically Post Traumatic Stress Disorder (PTSD). There is also evidence to support use in other diseases such as Parkinson’s Disease as the analogues can be engineered to select for specific neurological receptors."

Page 19 from this Presentation they already have an example of an MDMA like compound that by altering CH₃ they were able to get a non-psychoactive variation that could still work in reducing Dyskinesia when used in conjunction with L-DOPA, so yeah that is kind of a big deal.